What is the complete multidrug therapy regimen for treating leprosy, including dosing for paucibacillary and multibacillary disease?

Complete Multidrug Therapy Regimen for Leprosy

For paucibacillary (PB) leprosy, treat with rifampicin 600 mg monthly (supervised) plus dapsone 100 mg daily (self-administered) for 6 months; for multibacillary (MB) leprosy, treat with rifampicin 600 mg monthly (supervised), dapsone 100 mg daily, and clofazimine 300 mg monthly (supervised) plus 50 mg daily (self-administered) for 12 months. 1, 2

Paucibacillary Leprosy Treatment

• Duration: 6 months of multidrug therapy is sufficient for PB disease 3, 1
• Regimen components:
  • Rifampicin 600 mg once monthly (supervised dose) 3, 1
  • Dapsone 100 mg daily (self-administered) 3, 1
• Treatment endpoint: No maintenance therapy required after completion 3

Multibacillary Leprosy Treatment

The treatment duration and approach depends on bacterial load at diagnosis:

Standard MB Cases (BI <3 or fresh cases with BI ≥3)

• Duration: 12 months of MDT/MB 3, 1
• Regimen components:
  • Rifampicin 600 mg once monthly (supervised) 1, 2
  • Dapsone 100 mg daily (self-administered) 1, 2
  • Clofazimine 300 mg once monthly (supervised) plus 50 mg daily (self-administered) 1, 2
• Post-treatment: If BI becomes negative and active lesions resolve within 12 months, no maintenance therapy needed 3
• If still active: Add one additional year of MDT/MB if BI remains positive or active lesions persist 3

High Bacterial Load MB Cases (BI ≥3 at diagnosis)

• Initial duration: 24 months of MDT/MB 3
• Same drug regimen as standard MB cases 3
• Assessment at 2 years:
  • If BI becomes negative and active lesions resolve: stop treatment, no maintenance needed 3
  • If BI remains positive: add one additional year of MDT/MB (3 years total), then switch to maintenance therapy with dapsone and clofazimine until BI negativity and loss of active lesions 3

Important Clinical Considerations

Emerging evidence suggests standard 12-month therapy may be insufficient for high bacterial load cases. A 2023 study found that 20-24 out of 36 patients still had viable M. leprae after completing 12 months of WHO-recommended MDT, particularly those with BI of 3+ to 4+ 4. This supports the Japanese Leprosy Association's recommendation for extended therapy in high-burden disease 3.

Drug interactions matter during combination therapy. Rifampicin induces hepatic CYP450 enzymes, which decreases dapsone's plasma half-life and induces its own metabolism 5. However, this interaction is accounted for in the standard dosing regimens and does not require dose adjustment 5.

Alternative regimens exist but are not first-line. Monthly rifampicin, moxifloxacin, and minocycline (RMM) showed excellent tolerability and completion rates in a 2022 US case series, avoiding clofazimine-related skin hyperpigmentation 6. Novel agents like bedaquiline demonstrated complete clearance of M. leprae by 4 weeks in a 2024 proof-of-concept study 7. However, these remain investigational and should not replace standard WHO-recommended MDT in routine practice.

Common pitfall: Do not stop therapy prematurely in MB cases with high bacterial loads, as this increases relapse risk and continued community transmission 4. Always assess BI and clinical activity before discontinuing treatment in MB disease 3.